NCT04267926View on ClinicalTrials.gov

MitoQ for Fatigue in Multiple Sclerosis (MS)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

October 15, 2024

Study Completion Date

March 31, 2026

Conditions
Multiple SclerosisFatigue
Interventions
DRUG

20 mg MitoQ

a third of subject will receive 20mg of oral MitoQ

DRUG

Placebo

Subject will receive Placebo

DRUG

40mg of MitoQ

a third of subjects will receive 40mg of MitoQ

Trial Locations (1)

97207-2964

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors
lead

VA Office of Research and Development

FED